Cell Signaling Technology Announces Partnership with AstraZeneca to Identify Biomarkers for Kinase Inhibitor Lead Compounds
Beverly, MA and London, UK, June 12, 2004 — Cell Signaling Technology, Inc. (CST) announced today an agreement with AstraZeneca to perform a pilot study profiling select AstraZeneca compounds with CST’s Global Phospho-Signature technology to discover novel, informative biomarkers of protein tyrosine kinase (PTK) target inhibition. CST’s Global Phospho-Signature (GPS) phospho-proteomics technology is a patent-pending methodology combining immunoaffinity purification and mass spectroscopy to determine cellular PTK phosphorylation profiles (TKSignatures®). Biomarkers that are discovered with GPS may enable the development of profiling assays to monitor targeted therapeutic pharmacodynamics and efficacy.
“AstraZeneca’s kinase-targeted therapeutics provided an excellent context in which to demonstrate the value of CST’s Global Phospho-Signature capabilities,” said Christopher Bunker, CST’s Director of Pharma Services. “The TKSignatures® of kinase targets and kinase inhibitor response can provide information to enable the development of valuable and proprietary biomarker assays. CST integrated capabilities in antibody and immunoassay development will be available to AstraZeneca to rapidly translate GPS discoveries into validated biomarker assays.”
CST’s Global Phospho-Signature platform is the most comprehensive methodology for elucidating TKSignatures® of protein tyrosine kinase targets. GPS TKSignatures® have been discovered for multiple disease models and targets, and CST has identified thousands of novel phosphorylation sites.
About Cell Signaling Technology, Inc.
Cell Signaling Technology, Inc. has expertise and the market leadership position in the development and commercialization of phospho-specific antibodies and assays for kinase and pathway analysis. CST’s phospho-specific antibodies are validated in multiple assay platforms and are critical reagents in all stages of pharmaceutical drug discovery and development. CST has leveraged its antibody core capabilities to develop a superior phospho-proteomics platform that will be offered to enable more efficient and informative clinical trial design and strategic Rx/Dx partnership opportunities. More information on CST can be obtained at the Company’s website at www.cellsignal.com.
AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of over $18.8 billion and leading positions in sales of gastrointestinal, oncology, cardiovascular, neuroscience and respiratory products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global and European) as well as the FTSE4Good Index. Worldwide, AstraZeneca has six major research and development sites, four discovery facilities and a clinical research site, in total, employing more than 11,500 R&D staff members in Canada, France, India, Japan, Sweden, United Kingdom and the United States.
For more information, contact: